Peregrine Pharmaceuticals to Present at Biotech Showcase 2018

Peregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D., as President and Chief Executive Officer

Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2018 and Recent Developments

Peregrine Pharmaceuticals Declares Quarterly Dividend on its Series E Convertible Preferred Stock

Peregrine Pharmaceuticals to Report Financial Results for Second Quarter of Fiscal Year 2018 After Market Close on December 11, 2017

Peregrine Pharmaceuticals, Ronin Trading and SW Investment Management Announce Settlement Agreement

Peregrine Announces Date of 2017 Annual Meeting of Stockholders

Peregrine Pharmaceuticals Announces Appointment of Patrick Walsh to Board of Directors of Peregrine and Avid Bioservices

Peregrine Pharmaceuticals Announces Appointment of Mark R. Bamforth to Board of Directors of Peregrine and Avid Bioservices

Peregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018 and Recent Developments